Skip to Content

Iothalamate Pregnancy and Breastfeeding Warnings

Iothalamate is also known as: Conray, Conray-30, Conray-400, Conray-43, Cysto-Conray, Cysto-Conray II

Iothalamate Pregnancy Warnings

Use is not recommended unless clearly needed.

US FDA pregnancy category: B

Intravascular contrast agents may cross the placenta and can potentially produce transient fetal hypothyroidism. Reproduction studies in animals have revealed no evidence of impaired fertility or harm to the fetus. There are no adequate and well controlled studies in pregnant women.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Iothalamate Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Yes (unchanged)

Comments:
-The effects in the nursing infant are unknown.
-Use bottle feeding for 24 hours following the administration of this drug.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc, St. Louis, MO.

References for breastfeeding information

  1. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc, St. Louis, MO.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide